Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]

AI-generated source summary

The analysis assesses Rapport Therapeutics, indicating several positive signals, but overall concludes that the stock is not currently a buy but to hold. The price target for the next trading day is at $33.60, and has a stop-loss recommendation is set at $30.41, has high volatility but medium risk. Recent news indicates promising phase 2a trial results and underwritten public offering. Analyst ratings lean towards a sell consensus with negative price-to-earnings and price-to-book ratios and insider trades indicate slightly positive signals. There are buy signals from both short and long-term moving averages, yet with downside volume and some analyst sell recommendations; however system indicators show the stock price as currently undervalued.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   09 Sept 2025, 04:05 UTC

   The analyst published the original source item.

2. First prediction resolved

   09 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   09 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.